Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma.
In this GEN webinar, experts from WuXi AppTec will share essential strategies and methodologies for accelerating pre-clinical assessments of ADCs. This will include approaches for assessing the pharmacology, biotransformation, toxicokinetics, and immunogenicity of biologics early in their development. The webinar will offer methods for addressing ADC resistance as well as for metabolite profiling and identifying payload-related species for cleavable and non-cleavable ADCs.
In this webinar you’ll learn:
The complex biotransformation processes of ADCs and detailed methodologies for metabolite profiling of payload-related species and Drug-to-Antibody Ratio distribution
Related Resources
-
Advancing Antibody-Drug Conjugates (ADCs) with Novel Payloads and Their DMPK Considerations
ArticlesDec 10,2024 -
Spotlight on the DMPK and Bioanalysis Strategy of Antibody Oligonucleotide Conjugates (AOCs)
ArticlesNov 21,2024 -
In Vitro Metabolic Stability Evaluation of ADCs in Plasma and Whole Blood
PostersOct 17,2024
Related Services and Platforms
-
MetID (Metabolite Profiling and Identification)Learn More
-
Novel Drug Modalities DMPK Enabling PlatformsLearn More
-
In Vitro MetID (Metabolite Profiling and Identification)Learn More
-
In Vivo MetID (Metabolite Profiling and Identification)Learn More
-
Metabolite Biosynthesis and Structural CharacterizationLearn More
-
Metabolites in Safety Testing (MIST)Learn More
-
PROTAC DMPK ServicesLearn More
-
ADC DMPK ServicesLearn More
-
Oligo DMPK ServicesLearn More
-
PDC DMPK ServicesLearn More
-
Peptide DMPK ServicesLearn More
-
mRNA DMPK ServicesLearn More
-
Covalent Drugs DMPK ServicesLearn More
Stay Connected
Keep up with the latest news and insights.